Sudden cardiac death in patients with diabetes mellitus and chronic heart failure

Diabetes and Vascular Disease Research

Volumn 12, Issue 4, 2015, Pages 228-233

  Walker, Andrew M N ^a   Cubbon, Richard M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

chronic heart failure; diabetes; incidence; mortality; Sudden cardiac death

Indexed keywords

CARDIAC PATIENT; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DIABETIC PATIENT; HEART FAILURE; HUMAN; INCIDENCE; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; RISK ASSESSMENT; SUDDEN CARDIAC DEATH; CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; RISK FACTOR;

CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DIABETES MELLITUS; HEART FAILURE; HUMANS; INCIDENCE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 84936996839     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164115573225     Document Type: Review

References (44)

1. International Diabetes Federation (IDF). IDF Diabetes Atlas. 6th ed. Brussels, Belgium: IDF, 2013.
2. Authors/Task Force Members; Ryden L, Grant PJ, Anker SD,. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087.
3. Mainous AG 3rd, Tanner RJ, Baker R,. Prevalence of prediabetes in England from 2003 to 2011: population-based, cross-sectional study. BMJ Open 2014; 4: e005002.
4. Myerburg RJ, Kessler KM, Castellanos A,. Sudden cardiac death: structure, function, and time-dependence of risk. Circulation 1992; 85: I2-I10.
5. Cubbon RM, Gale CP, Kearney LC,. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Fail 2011; 4: 396-403.
6. Myerburg RJ, Mitrani R, Interian A Jr,. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 1998; 97: 1514-1521.
7. Zipes DP, Camm AJ, Borggrefe M,. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death); Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006; 27: 2099-2140.
8. Bertoia ML, Allison MA, Manson JE,. Risk factors for sudden cardiac death in post-menopausal women. J Am Coll Cardiol 2012; 60: 2674-2682.
9. Kannel WB, Wilson PW, D'Agostino RB,. Sudden coronary death in women. Am Heart J 1998; 136: 205-212.
10. Kucharska-Newton AM, Couper DJ, Pankow JS,. Diabetes and the risk of sudden cardiac death, the atherosclerosis risk in communities study. Acta Diabetol 2010; 47 (Suppl. 1): 161-168.
11. Laukkanen JA, Makikallio TH, Ronkainen K,. Impaired fasting plasma glucose and type 2 diabetes are related to the risk of out-of-hospital sudden cardiac death and all-cause mortality. Diabetes Care 2013; 36: 1166-1171.
12. Cubbon RM, Adams B, Rajwani A,. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res 2013; 10: 330-336.
13. Junttila MJ, Barthel P, Myerburg RJ,. Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. Heart Rhythm 2010; 7: 1396-1403.
14. MacDonald MR, Petrie MC, Varyani F,. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-1385.
15. Watanabe E, Tanabe T, Osaka M,. Sudden cardiac arrest recorded during Holter monitoring: prevalence, antecedent electrical events, and outcomes. Heart Rhythm 2014; 11: 1418-1425.
16. Huikuri HV, Castellanos A, Myerburg RJ,. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345: 1473-1482.
17. Walker A, Cubbon R, Kearney M,. Contemporary treatment strategies for type 2 diabetes-related macrovascular disease. Expert Rev Endocrinol Metabol 2014; 9: 641-658.
18. Forsen A, Kangro M, Sterner G,. A 14-year prospective study of autonomic nerve function in type 1 diabetic patients: association with nephropathy. Diabet Med 2004; 21: 852-858.
19. Larghat AM, Swoboda PP, Biglands JD,. The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging 2014; 15: 1368-1376.
20. Ewing DJ, Boland O, Neilson JM,. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991; 34: 182-185.
21. O'Brien IA, McFadden JP, Corrall RJ,. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991; 79: 495-502.
22. Veglio M, Chinaglia A, Cavallo-Perin P,. QT interval, cardiovascular risk factors and risk of death in diabetes. J Endocrinol Invest 2004; 27: 175-181.
23. Gami AS, Olson EJ, Shen WK,. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coll Cardiol 2013; 62: 610-616.
24. Singh JP, Larson MG, O'Donnell CJ,. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000; 86: 309-312.
25. Duckworth W, Abraira C, Moritz T,. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
26. Advance Collaborative Group; Patel A, MacMahon S, Chalmers J,. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
27. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP,. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
28. Yakubovich N, Gerstein HC,. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation 2011; 123: 342-348.
29. Bonds DE, Miller ME, Bergenstal RM,. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909.
30. Barthel P, Bauer A, Muller A,. Reflex and tonic autonomic markers for risk stratification in patients with type 2 diabetes surviving acute myocardial infarction. Diabetes Care 2011; 34: 1833-1837.
31. Stein PK, Deedwania P,. Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study). Am J Cardiol 2009; 103: 1495-1499.
32. Stein PK, Sanghavi D, Domitrovich PP,. Ambulatory ECG-based T-wave alternans predicts sudden cardiac death in high-risk post-MI patients with left ventricular dysfunction in the EPHESUS study. J Cardiovasc Electrophysiol 2008; 19: 1037-1042.
33. Ziegler D, Zentai CP, Perz S,. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008; 31: 556-561.
34. Wu L, Jiang Z, Li C,. Prediction of heart rate variability on cardiac sudden death in heart failure patients: a systematic review. Int J Cardiol 2014; 174: 857-860.
35. Levy WC, Mozaffarian D, Linker DT,. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113: 1424-1433.
36. Shindler DM, Kostis JB, Yusuf S,. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 1996; 77: 1017-1020.
37. Deedwania PC, Giles TD, Klibaner M,. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005; 149: 159-167.
38. Pitt B, Zannad F, Remme WJ,. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
39. Pitt B, Remme W, Zannad F,. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
40. Cubbon RM, Wheatcroft SB, Grant PJ,. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J 2007; 28: 540-545.
41. Bardy GH, Lee KL, Mark DB,. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
42. Moss AJ, Zareba W, Hall WJ,. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
43. Wittenberg SM, Cook JR, Hall WJ,. Comparison of efficacy of implanted cardioverter-defibrillator in patients with versus without diabetes mellitus. Am J Cardiol 2005; 96: 417-419.
44. Ruwald MH, Zareba W, Jons C,. Influence of diabetes mellitus on inappropriate and appropriate implantable cardioverter-defibrillator therapy and mortality in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial. Circulation 2013; 128: 694-701.